Exchange: NASDAQ·Updated 07:30 PM EST

ARCT News

News
all
press releases
Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Lowered by Zacks Research
Zacks Research downgraded shares of Arcturus Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Thursday...
MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Lowered by Zacks Research
Zacks Research downgraded shares of Arcturus Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Thursday...
MarketBeat
More News
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +56.67% and +116.10%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced its financial results for the quarter ended September 30, 2026, and provided corporate updates. The third...
Business Wire
Ocugen (OCGN) delivered earnings and revenue surprises of 0.00% and +34.55%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Ark Invest increased its exposure to several widely followed biotechnology stocks during the session.
Stocktwits
Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced that it will release its financial results for the quarter ended September 30, 2026, after the market close...
Business Wire
Here is how Agilon Health (AGL) and Arcturus Therapeutics (ARCT) have performed compared to their sector so far this year.
Zacks
Arcturus Therapeutics (NASDAQ:ARCT) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensiveread more...
Benzinga
No plague case has been confirmed, and no government orders have been announced, but outbreak-linked stocks jumped anyway.
Stocktwits
RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.
Zacks

Advertisement|Remove ads.